Preventing perinatal transmission of HIV: Your vigilance can pay off

,

Applied Evidence

Preventing perinatal transmission of HIV: Your vigilance can pay off

J Fam Pract. 2010 March;59(3):E1-E6

PDF Download

References

1. Force–Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. April 29, 2009. Available at: http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. Accessed January 25, 2010.

2. Kline MW. Perspectives on the pediatric HIV/AIDS pandemic: catalyzing access of children to care and treatment. Pediatrics. 2006;117:1388-1393.

3. Tolle M, Dewey D. Prevention of mother-to-child transmission of HIV infection. In: HIV Curriculum for the Health Professional. 4th ed. Houston, TX: BCM; 2009:90-119. Available at: http://bayloraids.org/curriculum/files/6.pdf. Accessed January 25, 2010.

4. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: toward universal access–recommendations for a public health approach. August 2006. Available at: http://www.who.int/hiv/pub/mtct/arv_guidelines_mtct.pdf. Accessed February 3, 2010.

5. Kourtis AP, Lee FK, Abrams EJ, et al. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis. 2006;6:726-732.

6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance in Women. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/slides/women/slides/Women.pdf. Accessed June 17, 2008.

7. Centers for Disease Control and Prevention. Cases of HIV Infection and AIDS in the United States and Dependent Areas, 2007. Available at http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2007report/default.htm. Accessed June 17, 2008.

8. Cohen MS. HIV and sexually transmitted diseases: lethal synergy. Top HIV Med. 2004;12:104-107.

9. Centers for Disease Control and Prevention. HIV transmission among black women—North Carolina, 2004. MMWR Morbid Mortal Wkly Rep. 2005;54:89-94.

10. Latka M. Drug-using women need comprehensive sexual risk reduction interventions. Clin Infect Dis. 2003;37(suppl S):S445-S450.

11. Kimani J, Kaul R, Nagelkerke NJ, et al. Reduced rates of HIV acquisition during unprotected sex by Kenyan female sex workers predating population declines in HIV prevalence. AIDS. 2008;22:131-137.

12. Centers for Disease Control and Prevention. Achievements in public health: reduction in perinatal transmission of HIV infection—United States, 1985-2005. MMWR Morbid Mortal Wkly Rep. 2006;55:592-597.

13. Lindau ST, Jerome J, Miller K, et al. Mothers on the margins: implications for eradicating perinatal HIV. Soc Sci Med. 2006;62:59-69.

14. Branson BM, Handsfield HH, Lampe MA, et al. Centers for Disease Control and Prevention. Revised recommendations for the HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR14):1-17.

15. Lampe MA. Rapid HIV testing in labor and delivery: a safety net to prevent perinatal transmission. Available at: http://www.cdc.gov/hiv/topics/testing/rapid/pdf/LampePlenary2.pdf. Accessed February 3, 2010.

16. Centers for Disease Control and Prevention One test. Two lives. HIV screening for prenatal care. Available at: http://www.cdc.gov/Features/1Test2Lives. Accessed February 3, 2010.

17. Conner EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of HIV type 1 with zidovudine treatment. N Engl J Med. 1994;33:1173-1180.

18. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.

19. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3:371-378.

20. Nwokike J, Torpey K, Amenyah R, et al. Health systems-level strategic framework for improving adherence to antiretroviral therapy. AIDS 2006 - XVI International AIDS Conference: Abstract CDB1245.

21. Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV transmission: additive protective effect of elective cesarean section and zidovudine prophylaxis. AIDS. 1998;12:205-210.

22. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet. 1999;353:1035-1039.

23. Zorrilla CD. HIV infection in women: perinatal issues and cervical cancer surveillance. Top HIV Med. 2007;15:1-5.

24. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21:929-938.

25. Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study. J Infect Dis. 2006;194:1089-1097.

26. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 1999;281:151-157.

27. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years—United States, 2010. MMWR Morbid Mortal Wkly Rep. 2010;58(51&52):1-4.

28. Anabwani GM, Woldetsadik EA, Kline MW. Treatment of human immunodeficiency virus (HIV) in children using antiretroviral drugs. Semin Pediatr Infect Dis. 2005;16:116-124.

29. Centers for Disease Control and Prevention. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. MMWR Recomm Rep. 2009;58(RR-11):1-176.

TABLE 2
Follow-up measures for infants exposed to maternal HIV^1,27

ZDV prophylaxis From birth to age 6 weeks
Diagnosis of HIV Virologic test (required for infants <18 months of age; HIV DNA PCR preferred) At birth (optional), 14 to 21 days, 1 to 2 months, 4 to 6 months If positive, repeat immediately on a separate specimen for confirmation; 2 positive HIV DNA PCR tests confirm a diagnosis of HIV infection HIV presumptively excluded (nonbreastfed infant): 2 or more negative tests, with 1 at ≥14 days and another at ≥1 month. HIV definitively excluded (nonbreastfed infant): 2 negative tests at ≥1 month and ≥4 months of age.
HIV ELISA 18 months. Confirmatory test if HIV DNA PCR tests performed as above are negative
Complete blood count At birth, when initiating ZDV prophylaxis, and at time of 1st HIV DNA PCR (2-3 weeks)
*Prophylaxis against Pneumocystis* pneumonia** Trimethoprim-sulfamethoxazole beginning at 6 weeks, with discontinuation of ZDV prophylaxis, unless HIV presumptively excluded (see above)
Routine Immunizations As per general US pediatric immunization schedule
DNA, deoxyribose nucleic acid; ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; PCR, polymerase chain reaction; ZDV, zidovudine.

CORRESPONDENCE
Michael A. Tolle, MD, Baylor College of Medicine, 6701 Fannin Street, CC1210, Houston, TX 77030; tolle@bcm.edu

Acknowledgements
The author thanks Heidi Schwarzwald, MD, Gordon Schutze, MD, and Mark Kline, MD, for their comments on this manuscript.